BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ameritox, Ltd. Symposium to Help Educate Physicians About Emerging Trends in Opioid, Designer Drug Misuse and Abuse at Third Annual CASIPPMeeting


11/9/2012 2:01:26 PM

BALTIMORE, Nov. 8, 2012 /PRNewswire/ -- AmeritoxSM, the nation's leader in medication monitoring solutions, today announced an upcoming symposium titled "Emerging Trends in Managing Opioid Abuse and Misuse: New Recommendations and Designer Drugs," to be held in conjunction with the third annual California Society of Interventional Pain Physicians (CASIPP) meeting in Newport Beach, Calif., on Nov. 10.

The symposium will feature leading pain expert Daniel Bennett, M.D., medical director, Integrative Treatment Centers, Westminster, Colo., along with Harry Leider, M.D., chief medical officer, Ameritox. Dr. Bennett will discuss the recently published "Recommendations for Urine Drug Monitoring as a Component of Opioid Therapy in the Treatment of Chronic Pain" created by pain medicine experts and facilitated by the School of Population Health at Thomas Jefferson University. The Recommendations provide real-world insights for physicians treating chronic pain patients, including which patients to test, how often to test, how to interpret results, and how to handle discrepancies based on specific results.

"Regardless of age or background, all patients have a degree of risk for misuse of opioids," explained Dr. Bennett. "For interventional pain physicians, who are truly central to both providing quality patient care and protecting public safety, understanding the technology and tools that are available to support clinical practice is particularly important. That's why I'm so pleased to be able to speak directly with CASIPP members about these recommendations. Routine monitoring with UDM is critical to maintaining patient safety."

Dr. Leider will discuss designer drugs such as "bath salts" and synthetic marijuana variants like "K2" and "Spice," which are manufactured versions of illicit substances created by chemists to bypass laws and provide a "legal high." In 2011, the National Poison Control Centers received more than 6,000 calls about synthetic cathinones (including bath salts), compared to only 300 in 2010. Moreover, the American Association of Poison Control Centers reported that the number of calls related to synthetic marijuana and/or K2/Spice more than doubled from 2010 to 2011.

"Supporting physicians who seek to ease patient suffering while protecting public safety is our singular focus at Ameritox," said Dr. Leider. "As new, dangerous drugs make their way into users' hands particularly synthetic drugs designed by street chemists in an effort to skirt the law the ability to screen for these compounds is critical for helping clinicians protect patients and their communities. We are committed not only to advancing the science of UDM, but to ensuring that all pain practitioners on the front lines have access to education around these issues that are so important to society."

The symposium will be held in the Catalina Room at the Resort at Pelican Hill from 5 to 6 p.m. A wine and cheese reception will begin at 4:30 p.m.

For additional information, visit www.ameritox.com.

About Ameritox
Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process Rx GuardianSM with Rx Guardian CDSM, the only pain medication monitoring process with a proprietary normalization algorithm and a reference database of pain patients clinically assessed for adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through prescription drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, on Facebook at facebook.com/ameritox, and on YouTube at www.youtube.com/ameritox.

© 2012 Ameritox Ltd. All rights reserved. Ameritox, Ameritox-Medication Monitoring Solutions, Rx Guardian, Rx Guardian INSIGHT and Rx Guardian CD are trademarks of Ameritox. Other trademarks are the property of their owners.

SOURCE Ameritox



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES